|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07D 409/10 | |
| A61K 31/381 | |||
| A61P 3/10 |
| (11) | Number of the document | 3298007 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16730933.5 |
| Date of filing the European patent application | 2016-05-18 | |
| (97) | Date of publication of the European application | 2018-03-28 |
| (45) | Date of publication and mention of the grant of the patent | 2020-07-22 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2016/033071 |
| Date | 2016-05-18 |
| (87) | Number | WO 2016/191173 |
| Date | 2016-12-01 |
| (30) | Number | Date | Country code |
| 201562165265 P | 2015-05-22 | US |
| (72) |
BRESLIN, David T., US
FAWZY, Nagy E., US
SCHAEFER, John, US
|
| (73) |
Janssen Pharmaceutica NV,
Turnhoutseweg 30, 2340 Beerse,
BE
|
| (54) | ANHYDROUS CRYSTALLINE FORM OF (1S)-1,5-ANHYDRO-1-[3-[[5-(4-FLUOROPHENYL)-2-THIENYL]METHYL]-4-METHYLPHENYL]-D-GLUCITOL |
| ANHYDROUS CRYSTALLINE FORM OF (1S)-1,5-ANHYDRO-1-[3-[[5-(4-FLUOROPHENYL)-2-THIENYL]METHYL]-4-METHYLPHENYL]-D-GLUCITOL |